BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 31959133)

  • 1. Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
    Umphlett M; Shea S; Tome-Garcia J; Zhang Y; Hormigo A; Fowkes M; Tsankova NM; Yong RL
    BMC Cancer; 2020 Jan; 20(1):47. PubMed ID: 31959133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Evolution of
    Draaisma K; Chatzipli A; Taphoorn M; Kerkhof M; Weyerbrock A; Sanson M; Hoeben A; Lukacova S; Lombardi G; Leenstra S; Hanse M; Fleischeuer R; Watts C; McAbee J; Angelopoulos N; Gorlia T; Golfinopoulos V; Kros JM; Verhaak RGW; Bours V; van den Bent MJ; McDermott U; Robe PA; French PJ
    J Clin Oncol; 2020 Jan; 38(1):81-99. PubMed ID: 31743054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.
    Favero F; McGranahan N; Salm M; Birkbak NJ; Sanborn JZ; Benz SC; Becq J; Peden JF; Kingsbury Z; Grocok RJ; Humphray S; Bentley D; Spencer-Dene B; Gutteridge A; Brada M; Roger S; Dietrich PY; Forshew T; Gerlinger M; Rowan A; Stamp G; Eklund AC; Szallasi Z; Swanton C
    Ann Oncol; 2015 May; 26(5):880-887. PubMed ID: 25732040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic alterations predictive of response to radiosurgery in recurrent IDH-WT glioblastoma.
    Dono A; Amsbaugh M; Martir M; Smilie RH; Riascos RF; Zhu JJ; Hsu S; Kim DH; Tandon N; Ballester LY; Blanco AI; Esquenazi Y
    J Neurooncol; 2021 Mar; 152(1):153-162. PubMed ID: 33492602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spinal metastasis of glioblastoma multiforme before gliosarcomatous transformation: a case report.
    Hsu BH; Lee WH; Yang ST; Han CT; Tseng YY
    BMC Neurol; 2020 May; 20(1):178. PubMed ID: 32393192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glioblastoma Recurrence and the Role of O
    Storey K; Leder K; Hawkins-Daarud A; Swanson K; Ahmed AU; Rockne RC; Foo J
    JCO Clin Cancer Inform; 2019 Feb; 3():1-12. PubMed ID: 30758983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
    Nguyen SA; Stechishin OD; Luchman HA; Lun XQ; Senger DL; Robbins SM; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Sep; 20(18):4894-903. PubMed ID: 25078279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of MGMT promoter methylation on the survival of TMZ treated
    Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
    Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency.
    AlHarbi M; Ali Mobark N; AlMubarak L; Aljelaify R; AlSaeed M; Almutairi A; Alqubaishi F; Hussain ME; Balbaid AAO; Said Marie A; AlSubaie L; AlShieban S; alTassan N; Ramkissoon SH; Abedalthagafi M
    Oncologist; 2018 Dec; 23(12):1401-1406. PubMed ID: 30104292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype.
    Schwartz C; Romagna A; Machegger L; Weiss L; Huemer F; Fastner G; Kleindienst W; Weis S; Greil R; Winkler PA
    World Neurosurg; 2018 Dec; 120():442-447. PubMed ID: 30253992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating genomic signatures into surgical and medical decision-making for elderly glioblastoma patients.
    Ene CI; Cimino PJ; Fine HA; Holland EC
    Neurosurg Focus; 2020 Oct; 49(4):E11. PubMed ID: 33002863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lynch syndrome-associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome.
    Yang C; Austin F; Richard H; Idowu M; Williamson V; Sabato F; Ferreira-Gonzalez A; Turner SA
    Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31604779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
    Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK
    Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
    Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
    Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment considerations for MGMT-unmethylated glioblastoma.
    Taylor JW; Schiff D
    Curr Neurol Neurosci Rep; 2015 Jan; 15(1):507. PubMed ID: 25394859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
    Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
    Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape.
    Mohme M; Maire CL; Schliffke S; Joosse SA; Alawi M; Matschke J; Schüller U; Dierlamm J; Martens T; Pantel K; Riethdorf S; Lamszus K; Westphal M
    Acta Neuropathol Commun; 2020 Mar; 8(1):28. PubMed ID: 32151286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
    Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H
    J Neurosurg; 2018 May; 130(3):780-788. PubMed ID: 29726772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.